Trials / Completed
CompletedNCT01765868
A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers
A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Portola Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a open label, single center, single oral dose, study of PRT054021, in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Betrixaban | Single Oral dose 80 mg betrixaban and Single IV (15 ml) carbon 14 80 micrograms Betrixaban administered over 15 minutes, 2 hours after the oral dose |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2013-01-10
- Last updated
- 2023-08-08
Source: ClinicalTrials.gov record NCT01765868. Inclusion in this directory is not an endorsement.